Rational Design and Pharmacomodulation of 18F-Labeled Biotin/FAPI-Conjugated Heterodimers.

Due to the complex heterogeneity in different cancer types, the heterodimeric strategy has been intensively practiced to improve the effectiveness of tumor diagnostics. In this study, we developed a series of novel 18F-labeled biotin/FAPI-conjugated heterobivalent radioligands ([18F]AlF-NSFB, [18F]AlF-NSFBP2, and [18F]AlF-NSFBP4), synergistically targeting both fibroblast activation protein (FAP) and biotin receptor (BR), to enhance specific tumor uptake and retention. The in vitro and in vivo biological properties of these dual-targeting tracers were evaluated, with a particular focus on positron emission tomography imaging in A549 and HT1080-FAP tumor-bearing mice. Notably, in comparison to the corresponding FAP-targeted monomer [18F]AlF-NSF, biotin/FAPI-conjugated heterodimers exhibited a high uptake in tumor and prolong retention. In conclusion, as a proof-of-concept study, the findings validated the superiority of biotin/FAPI-conjugated heterodimers and the positive influence of biotin and linker on pharmacokinetics of radioligands. Within them, the bispecific [18F]AlF-NSFBP4 holds significant promise as a candidate for further clinical translational studies.

[1]  Hua Wu,et al.  Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy , 2023, The Journal of Nuclear Medicine.

[2]  R. Mansi,et al.  Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides , 2023, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Zhaohui Zhu,et al.  Dual targeting PET tracer [68Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study , 2023, Theranostics.

[4]  W. Zhang,et al.  Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging , 2023, Frontiers in Bioengineering and Biotechnology.

[5]  J. Joyce,et al.  The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. , 2023, Cancer cell.

[6]  Y. Yao,et al.  Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging. , 2023, Molecular pharmaceutics.

[7]  Zhide Guo,et al.  Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD , 2022, Theranostics.

[8]  Hao Peng,et al.  Advances of cancer-associated fibroblasts in liver cancer , 2022, Biomarker Research.

[9]  T. Lammers,et al.  Cancer-associated Fibroblasts: Origin, Function, Imaging, and Therapeutic Targeting. , 2022, Advanced drug delivery reviews.

[10]  Angela C. Rieger,et al.  Non-oncologic incidental uptake on FAPI PET/CT imaging. , 2022, The British journal of radiology.

[11]  Jinming Yu,et al.  [18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Jiawei Zhong,et al.  Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/FAP Heterodimers for Tumor Imaging , 2022, Pharmaceuticals.

[13]  Y. Seimbille,et al.  Tumor Microenvironment Responsive "Head-to-Foot" Self-Assembly Nanoplatform for Positron Emission Tomography Imaging in Living Subjects. , 2021, ACS nano.

[14]  Zhide Guo,et al.  Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer , 2021, The Journal of Nuclear Medicine.

[15]  R. Kalluri,et al.  Clinical and therapeutic relevance of cancer-associated fibroblasts , 2021, Nature Reviews Clinical Oncology.

[16]  J. Marchal,et al.  Cancer: a mirrored room between tumor bulk and tumor microenvironment , 2021, Journal of Experimental & Clinical Cancer Research.

[17]  R. Hoffman,et al.  Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates , 2021, Molecules.

[18]  D. Neri,et al.  An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications , 2021, Proceedings of the National Academy of Sciences.

[19]  M. Pomper,et al.  Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules. , 2021, Journal of medicinal chemistry.

[20]  Nan Li,et al.  Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  C. van Nostrum,et al.  Biotin-decorated all-HPMA polymeric micelles for paclitaxel delivery. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Torsten Kuwert,et al.  Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor , 2020, The Journal of Nuclear Medicine.

[23]  Thomas Lindner,et al.  Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention , 2019, The Journal of Nuclear Medicine.

[24]  H. Kauczor,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[25]  Thomas Lindner,et al.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.

[26]  P. Paira,et al.  Biotin conjugated organic molecules and proteins for cancer therapy: A review. , 2018, European journal of medicinal chemistry.

[27]  C. Fernández-Mejía,et al.  Pharmacological Effects of Biotin in Animals. , 2017, Mini reviews in medicinal chemistry.

[28]  O. Schilling,et al.  Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy , 2014, Proteomics. Clinical applications.

[29]  Chuda Chittasupho.  Multivalent ligand: design principle for targeted therapeutic delivery approach. , 2012, Therapeutic delivery.

[30]  P. Kuo,et al.  The tumor microenvironment. , 2012, Surgical oncology.

[31]  G. Russell-Jones,et al.  Preliminary studies on the selective accumulation of vitamin-targeted polymers within tumors , 2011, Journal of drug targeting.

[32]  Xianrui Zhao,et al.  Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. , 2010, Bioconjugate chemistry.

[33]  J. Zempleni,et al.  Biotin supply affects rates of cell proliferation, biotinylation of carboxylases and histones, and expression of the gene encoding the sodium-dependent multivitamin transporter in JAr choriocarcinoma cells , 2004, European journal of nutrition.